OraSure Technologies, Inc. (OSUR) Bundle
A Brief History of Orasure Technologies, Inc.
Orasure Technologies, Inc. is a leader in the field of diagnostics and sample collection technologies. Established in 1990, the company has evolved significantly over the years to meet the changing demands of the healthcare landscape.
Company Overview
As of September 30, 2024, Orasure Technologies reported a net loss of $4.5 million for the third quarter, a decrease from a net income of $11.2 million in the same quarter of 2023. The company's total revenues for the nine months ended September 30, 2024, amounted to $148.4 million, a steep decline of 55% compared to $329.6 million for the same period in 2023.
Financial Performance
Orasure's consolidated net revenues have been impacted by the decline in COVID-19 diagnostic sales, which dropped by 80% to $44.2 million for the nine months ended September 30, 2024, from $215.9 million in the same period of 2023. The table below summarizes the company's revenues by product line:
| Product Line | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | % Change |
|---|---|---|---|
| COVID-19 Diagnostics | $44,222 | $216,115 | -80% |
| HIV Products | $45,379 | $46,518 | -2% |
| Molecular Sample Management Solutions | $36,237 | $41,230 | -12% |
| Risk Assessment Testing | $6,265 | $7,540 | -17% |
| Other Products | $1,802 | $1,739 | 4% |
Cost Management and Expenses
The company has implemented significant cost-cutting measures, resulting in a decrease in operating expenses of approximately 22.9% to $77.3 million for the nine months ended September 30, 2024, compared to $100.2 million for the same period in 2023. Research and development expenses also saw a reduction of 25% to $20 million in 2024.
Stockholder’s Equity
As of September 30, 2024, Orasure's stockholders' equity stood at approximately $425.6 million. The company has seen fluctuations in its stockholder equity, with a notable decline in accumulated deficit to $92.6 million.
Future Outlook
Orasure Technologies is focusing on strategic investments, including a $30 million investment in Sapphiros, aimed at expanding its diagnostic capabilities. The company is also transitioning away from its molecular services line of business, which is expected to be completed by the end of 2024.
Recent Developments
The company has indicated plans to consolidate operations and discontinue certain product lines, including risk assessment testing, to streamline its operations and focus on core areas of growth.
Conclusion
Overall, Orasure Technologies continues to adapt to the evolving healthcare environment while managing its financial performance amid significant challenges in its product lines.
A Who Owns OraSure Technologies, Inc. (OSUR)
Major Shareholders
As of 2024, the ownership structure of OraSure Technologies, Inc. is as follows:
| Shareholder | Shares Owned | Ownership Percentage |
|---|---|---|
| BlackRock, Inc. | 7,800,000 | 10.5% |
| The Vanguard Group, Inc. | 6,500,000 | 8.8% |
| Dimensional Fund Advisors LP | 4,200,000 | 5.6% |
| SSgA Funds Management, Inc. | 3,800,000 | 5.1% |
| Other Institutional Investors | 15,000,000 | 20.0% |
| Insider Holdings | 2,000,000 | 2.7% |
| Public Float | 30,000,000 | 40.3% |
Recent Stock Performance
As of September 30, 2024, OraSure Technologies, Inc. (OSUR) stock was trading at approximately $5.70 per share. The stock has seen a significant decline of 55% in total revenues compared to the same period in the previous year, reflecting the challenges faced by the company in the diagnostics market.
Financial Overview
Financial data for the nine months ended September 30, 2024, is summarized in the table below:
| Financial Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $148,382 |
| Net Loss | $(8,706) |
| Cash and Cash Equivalents | $278,571 |
| Total Assets | $464,085 |
| Total Liabilities | $38,520 |
| Total Stockholders' Equity | $425,565 |
Recent Corporate Actions
In 2024, OraSure Technologies executed a reduction in workforce, which included significant layoffs due to strategic restructuring aimed at consolidating operations. The total costs associated with these actions amounted to approximately $3.3 million.
Market Trends and Future Outlook
The company's diagnostics segment, particularly its COVID-19 testing products, has experienced a steep decline in demand, accounting for only $44.2 million in revenue for the nine months ended September 30, 2024, down from $216.1 million in the same period in 2023. This downturn is expected to continue as the market stabilizes post-pandemic.
OraSure Technologies, Inc. (OSUR) Mission Statement
Mission Statement Overview
OraSure Technologies, Inc. is dedicated to providing innovative, accurate, and reliable diagnostic solutions that empower healthcare professionals and improve patient outcomes. The mission reflects the company's commitment to addressing critical health challenges through advanced technology and comprehensive services.
Core Values
- Innovation: Continuously advancing diagnostic technology to meet the evolving needs of the healthcare community.
- Quality: Maintaining the highest standards in product development and service delivery.
- Integrity: Upholding ethical practices and transparency in all business operations.
- Collaboration: Partnering with healthcare providers, researchers, and organizations to enhance public health.
Financial Performance
As of September 30, 2024, OraSure Technologies reported a net revenue of $148.4 million, a significant decrease of 55% compared to $329.6 million for the same period in 2023. This decline was primarily attributed to reduced demand for COVID-19 testing products.
| Revenue Category | 2024 (Nine Months) | 2023 (Nine Months) | % Change |
|---|---|---|---|
| Diagnostics | $57.2 million | $56.5 million | +1% |
| COVID-19 Diagnostics | $44.2 million | $215.9 million | -80% |
| Molecular Sample Management Solutions | $36.2 million | $41.2 million | -12% |
| Risk Assessment Testing | $6.3 million | $7.5 million | -17% |
| Other Products and Services | $1.8 million | $1.7 million | +4% |
Operational Metrics
Operating loss for the nine months ended September 30, 2024 was $15.8 million, compared to an operating income of $28.8 million for the same period in 2023. This shift highlights the impact of reduced revenues and ongoing cost management measures.
Research and Development Investments
Research and development expenses decreased to $20.0 million for the nine months ended September 30, 2024, down from $26.7 million in 2023, reflecting a strategic focus on essential projects.
Market Position and Strategy
OraSure Technologies is positioned to leverage its expertise in diagnostics to address emerging health threats and enhance its product portfolio. The company aims to expand its market presence through targeted innovations and strategic collaborations.
Conclusion
The mission of OraSure Technologies, Inc. underscores its commitment to delivering high-quality diagnostic solutions and improving health outcomes globally. As the company navigates market challenges, it remains focused on innovation and strategic growth initiatives.
How OraSure Technologies, Inc. (OSUR) Works
Company Overview
OraSure Technologies, Inc. specializes in developing, manufacturing, and distributing oral fluid diagnostic products, including tests for infectious diseases and molecular sample management solutions. The company operates primarily in the diagnostics segment and has made significant adjustments in response to market changes, especially post-COVID-19.
Financial Performance
As of September 30, 2024, OraSure reported a net loss of $4.5 million, a significant decrease compared to a net income of $11.2 million for the same period in 2023. The total net revenues for the nine months ended September 30, 2024, were $148.4 million, down from $329.6 million in the previous year, reflecting a 55% decline.
| Financial Metrics | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Revenues | $39.9 million | $89.2 million | $148.4 million | $329.6 million |
| Net Income (Loss) | $(4.5) million | $11.2 million | $(8.7) million | $33.6 million |
| Operating Income (Loss) | $(6.0) million | $10.9 million | $(15.8) million | $28.8 million |
| Research & Development Expenses | $5.6 million | $8.5 million | $20.0 million | $26.7 million |
| Sales & Marketing Expenses | $7.6 million | $8.7 million | $24.0 million | $29.4 million |
| General & Administrative Expenses | $9.8 million | $10.1 million | $33.3 million | $44.2 million |
| Cash and Cash Equivalents | $278.6 million | N/A | $278.6 million | $290.4 million |
Revenue Breakdown
The decline in revenue can be attributed to decreased demand for COVID-19 testing products, specifically the InteliSwab® tests. The following table outlines the revenue by product line for the nine months ended September 30, 2024.
| Product Line | 9M 2024 Revenue (in thousands) | 9M 2023 Revenue (in thousands) | % Change |
|---|---|---|---|
| HIV Diagnostics | $45,379 | $46,518 | -2% |
| COVID-19 Diagnostics | $44,222 | $216,115 | -80% |
| Molecular Sample Management | $36,237 | $41,230 | -12% |
| Risk Assessment Testing | $6,265 | $7,540 | -17% |
| Other Products | $1,802 | $1,739 | +4% | Molecular Services | $1,692 | $3,567 | -53% |
Operational Changes
In response to declining revenues, OraSure has undertaken workforce reductions and strategic business exits, including the discontinuation of its Diversigen molecular services line. The company executed a reduction in workforce that led to termination benefits totaling approximately $404,000 for the first nine months of 2024.
Liquidity and Capital Resources
As of September 30, 2024, OraSure's cash and cash equivalents amounted to $278.6 million, with working capital reported at $322.4 million. This reflects a decrease from $346.9 million as of December 31, 2023, primarily due to strategic investments and operational costs.
Income Tax and Deferred Revenue
For the nine months ended September 30, 2024, OraSure recorded an income tax expense of $1.0 million compared to $2.0 million in 2023. Deferred revenue stood at $1.6 million as of September 30, 2024, compared to $1.2 million at the end of 2023.
| Tax Expense | 9M 2024 | 9M 2023 |
|---|---|---|
| State Income Tax Expense | $(0.2) million | $2.4 million |
| Foreign Income Tax Expense | $1.3 million | $0.4 million |
Outlook
OraSure anticipates ongoing challenges in revenue generation, particularly in COVID-19 diagnostics and molecular services, with expectations of continued revenue declines in these areas through the end of 2024.
How OraSure Technologies, Inc. (OSUR) Makes Money
Revenue Streams
OraSure Technologies, Inc. generates revenue primarily through diagnostic products, molecular sample management solutions, and non-product services. The company's consolidated net revenues for the nine months ended September 30, 2024, were $148.4 million, down from $329.6 million for the same period in 2023, representing a 55% decrease.
| Revenue Category | 2024 (in thousands) | 2023 (in thousands) | % Change | % of Total Revenue 2024 | % of Total Revenue 2023 |
|---|---|---|---|---|---|
| Diagnostics | $57,162 | $56,475 | 1% | 39% | 17% |
| COVID-19 Diagnostics | $44,186 | $215,876 | (80)% | 30% | 65% |
| Molecular Sample Management Solutions | $36,237 | $41,230 | (12)% | 24% | 13% |
| Risk Assessment Testing | $6,265 | $7,540 | (17)% | 4% | 2% |
| Other Products and Services | $1,802 | $1,739 | 4% | 1% | 1% |
| Molecular Services | $1,692 | $3,567 | (53)% | 1% | 1% |
| Non-Product and Services Revenues | $1,002 | $2,925 | (66)% | 1% | 1% |
| Total Net Revenues | $148,382 | $329,591 | (55)% | 100% | 100% |
Key Product Lines
OraSure's key product lines include:
- HIV, HCV, and Syphilis testing products.
- Molecular sample management solutions including genomics and microbiome products.
- COVID-19 diagnostics, although this segment has seen a significant decline in demand.
- Risk assessment testing products, which are expected to be phased out.
Financial Performance
For the nine months ended September 30, 2024, the company reported a net loss of $8.7 million compared to a net income of $33.6 million for the same period in 2023. The operating loss for the nine months was $15.8 million, sharply down from an operating income of $28.8 million in 2023.
| Financial Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Revenue | $148,382 | $329,591 |
| Net Income (Loss) | $(8,706) | $33,582 |
| Operating Income (Loss) | $(15,832) | $28,786 |
| Gross Profit | $65,824 | $136,526 |
| Operating Expenses | $81,656 | $107,740 |
Cost Management
The company has implemented cost-saving measures, resulting in a 22.9% decrease in operating expenses for the nine months ended September 30, 2024, down to $77.3 million from $100.2 million in 2023. Key reductions were noted in:
- Research and Development: Decreased by 25% to $20 million.
- Sales and Marketing: Decreased by 18% to $24 million.
- General and Administrative: Decreased by 25% to $33 million.
Market Trends and Future Outlook
COVID-19 testing revenue has significantly decreased, with a reported drop of 80% to $44.2 million for the nine months ended September 30, 2024, from $215.9 million in the same period in 2023. The decline is attributed to reduced demand and fulfillment of existing contracts.
Geographic Revenue Distribution
Revenue distribution by geographic area for the nine months ended September 30, 2024 showed significant reliance on the U.S. market:
| Geographic Area | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) |
|---|---|---|
| United States | $115,055 | $296,815 |
| Europe | $5,892 | $6,297 |
| Other Regions | $27,435 | $26,479 |
Conclusion of Revenue Performance
OraSure Technologies, Inc. continues to navigate a challenging market environment with substantial revenue declines in key product areas, particularly COVID-19 diagnostics. The company is focusing on cost management and strategic pivots to align with changing market demands.
OraSure Technologies, Inc. (OSUR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- OraSure Technologies, Inc. (OSUR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of OraSure Technologies, Inc. (OSUR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View OraSure Technologies, Inc. (OSUR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.